Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results

Author:Querol, Luis   Lewis, Richard A.   Hartung, Hans-Peter   van Doorn, Pieter A.   Lin, Jie   Dionne, Annie   Attarian, Shahram   Wallstroem, Erik   Auwarter, Kristen   Lu, Yi   Alonso-Alonso, Miguel   Atassi, Nazem   Hughes, Richard A. C.   

Session Name:S2: Updates on Motor Neuron and Peripheral Nerve Disorders  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:S2.008  

Author Institution:

Efficacy and Safety of Tolebrutinib Versus Placebo in Primary Progressive Multiple Sclerosis: Results from the Phase Three PERSEUS Trial

Author:Fox, Robert   Bar-Or, Amit   Vermersch, Patrick   Oreja Guevara, Celia   Traboulsee, Anthony   Giovannoni, Gavin   Syed, Sana   Sun, Furong   Salloum, Naji   Turner, Timothy   Wallstroem, Erik   Reich, Daniel   

Session Name:PL6: Contemporary Clinical Issues Plenary Session  

Topic:Neurohospitalist  

Program Number:PL6.003  

Author Institution:

Riliprubart Phase Three MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally

Author:Sommer, Claudia   Querol, Luis   Allen, Jeffrey   Merkies, Ingemar S.J.   van Doorn, Pieter A.   Wallstroem, Erik   Lu, Yi   Xiong, Li   Alonso-Alonso, Miguel   Atassi, Nazem   Lewis, Richard A.   

Session Name:P1: Neuromuscular and Clinical Neurophysiology (EMG): Autoimmune Neuropathies  

Topic:Multiple Sclerosis  

Program Number:P1.020  

Author Institution:

FREXADIGITAL AI Substudy: AI-based Smartphone Video Assessments of Motor Function in RMS and nrSPMS Population

Author:Kanlikilicer, Pinar   Chernova, Julia   Walrath, Levi   Planas, Albert Pla   Sarangi, Amrut   Kamel, Mena   Sarker, Hillol   Benlahcen, Karim   Truffinet, Philippe   Orozco, Luis   Wallstroem, Erik   Gargaun, Elena   

Session Name:P5: Multiple Sclerosis: Digital Health, Biomarkers, and Artificial Intelligence 2  

Topic:Neuro Trauma and Sports Neurology  

Program Number:P5.007  

Author Institution:

Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension

Author:Vermersch, Patrick   Krieger, Stephen   Wiendl, Heinz   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Montalban, Xavier   Saubadu, Stephane   Luo, Xiaodong   Smyth, Brendan   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Giovannoni, Gavin   

Session Name:P7: Multiple Sclerosis: Clinical Trials 1  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:P7.003  

Author Institution: